Zogenix, Inc. reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome. The study results, which are consistent with those reported in Study 1, Zogenix’s first pivotal Phase 3 study, successfully met the primary endpoint and all key secondary endpoints, demonstrating that ZX008, at a dose of 0.5 mg/kg/day (maximum 20 mg/day), is superior to placebo when added to a stiripentol regimen.
July 12, 2018
September 16, 2020
Body Cooling May Shorten Refractory Seizures in Dravet and Other Epilepsies
Used in addition to standard treatments, therapeutic hypothermia – based on lowering the body’s temperature – can shorten the duration of long-lasting seizures in drug-resistant forms of epilepsy, a study finds.